The Pulmonary Hypertension Association of Canada (PHA Canada) will mark the 6th annual World Pulmonary Hypertension Day on May 05, 2017 with the launch of Sometimes It’s PH, a new educational campaign targeting medical professionals. On May 05th, PHA Canada will release its new www.SometimesItsPH.ca website featuring information on pulmonary hypertension (PH) including its signs and symptoms, risk factors, diagnosis, and treatment.
An article published in Experimental Biology and Medicine (Volume 242, Issue 5, March, 2017) identifies a new signaling pathway that promotes heart failure in pulmonary hypertension. The study, led by Dr. Matthias Brock, from the Division of Pulmonology, University Hospital of Zurich, University of Zurich in Switzerland, reports that inhibition of MALAT1, a long noncoding RNA, reduces heart hypertrophy in mice with pulmonary hypertension.
Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted a label extension for dosage and administration for "Epoprostenol ACT" (0.5 mg and 1.5 mg) for the treatment of pediatric patients with pulmonary arterial hypertension (PAH).
In recent years, treatment advances have improved the survival rates of individuals with pulmonary arterial hypertension (PAH), a rare but devastating disease that affects an estimated 10 to 52 people per million.1,2 In addition, developments in genetics and genomics technology have begun to illuminate the mechanisms underlying the pathogenesis of PAH.
The discovery of a molecular factor that triggers blood clots in lung arteries may explain why chronic thromboembolic pulmonary hypertension (CTEPH) often occurs in patients without traditional clotting risk factors, according to a study.
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 (PDE-5) inhibitors in pediatric patients with pulmonary hypertension published Feb. 24, 2017 in Pediatrics demonstrates that scientific evidence supports the use of this class of medications in infants, neonates and children with pulmonary hypertension. In this review, these medicines were shown to improve echocardiography measurements, cardiac catheteriza…
The Montreal Heart Institute is proud to announce the opening of the very first electrophysiology laboratory (EP Lab) equipped with robotic and magnetic navigation and dedicated to congenital heart diseases in Canada. Congenital heart diseases are cardiac malformations that affect approximately 1% of all Canadians. “The eimplementation of this cutting edge technology is a major advance. Thanks to this new lab, we will be able to perform intervent…